Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
RATIONALE: Epoetin alfa may stimulate red blood cell production and may help improve
 cancer-related anemia and fatigue. Steroid therapy with dexamethasone may increase the
 effectiveness of epoetin alfa. It is not yet known if epoetin alfa is more effective with or
 without dexamethasone in treating anemia-related fatigue in patients with prostate cancer.

 PURPOSE: This randomized phase III trial is studying epoetin alfa and dexamethasone to see
 how well they work compared to epoetin alfa alone in treating anemia-related fatigue in
 patients with prostate cancer that is refractory to treatment with hormone therapy.
OBJECTIVES:

 -  Compare the effect of epoetin alfa with or without dexamethasone on the level of
 cancer-related fatigue measured by the FACIT fatigue subscale, in patients with
 hormone-refractory prostate cancer.

 -  Compare the effect of these regimens on increasing hemoglobin levels in these patients.

 -  Compare the effect of these regimens on palliation of other disease-related symptoms and
 on functional status and overall quality of life of these patients.

 -  Compare the survival rate of these regimens in these patients.

 -  Compare the toxicity profile of these regimens in these patients.

 -  Determine the incidence of adrenal suppression in these patients after receiving
 dexamethasone therapy.

 OUTLINE: This is a randomized, multicenter study. Patients are stratified according to usual
 fatigue severity on the Brief Fatigue Inventory numerical scale (3-6 vs 7-10) and hemoglobin
 level (8-10 g/dL vs 10.1-11.9 g/dL). Patients are randomized to 1 of 2 treatment arms.

 -  Arm I: Patients receive epoetin alfa subcutaneously once a week.

 -  Arm II: Patients receive epoetin alfa as in arm I and oral dexamethasone once a day.

 In both arms, treatment continues for 12 weeks in the absence of unacceptable toxicity.

 Quality of life and fatigue are assessed at baseline and then at 4, 8, and 12 weeks.

 Patients are followed for 3 years.

 PROJECTED ACCRUAL: A total of 282 patients (141 per treatment arm) will be accrued for this
 study within approximately 3 years.
DISEASE CHARACTERISTICS:

 -  Histologically confirmed prostate cancer

 -  Hormone-refractory disease as evidenced by progression on bone scan or CT scan
 with a rising prostate-specific antigen

 -  Prior bilateral orchiectomy OR other primary hormonal therapy (e.g., estrogen therapy
 or luteinizing hormone-releasing hormone analog [LHRH] and flutamide) with evidence of
 treatment failure

 -  Concurrent continual LHRH agonist therapy (e.g., depot leuprolide or goserelin)
 required for patients who have not undergone bilateral orchiectomy

 -  Must have anemia with hemoglobin ≥ 8 g/dL and < 12 g/dL within the past 14 days

 -  Must be iron replete (i.e., ferritin > 50 ng/mL) within the past 30 days

 -  Presence of fatigue with usual fatigue severity ≥ 3 on the 0-10 numerical scale of the
 Brief Fatigue Inventory within the past 14 days

 PATIENT CHARACTERISTICS:

 Age

 -  18 and over

 Performance status

 -  ECOG 0-3

 Life expectancy

 -  Not specified

 Hematopoietic

 -  See Disease Characteristics

 -  No disseminated intravascular coagulation

 -  No autoimmune hemolytic anemia

 Hepatic

 -  AST and ALT ≤ 2 times upper limit of normal

 -  No prior hemochromatosis or iron intolerance

 Renal

 -  Creatinine < 2.5 mg/dL

 Cardiovascular

 -  Adequate blood pressure (i.e., systolic blood pressure < 140 mm Hg and diastolic blood
 pressure < 90 mm Hg) (treated or untreated)

 -  No history of thromboembolic events

 -  No unstable angina

 -  No poorly controlled cardiac disease

 Other

 -  Fertile patients must use effective contraception

 -  Able to read, understand, and answer questions on the symptom and quality of life
 study instruments

 -  No ongoing chronic hemorrhage (e.g., gross hematuria due to advanced prostate cancer)*
 NOTE: *Microscopic hematuria allowed

 -  No acute or subacute illness that may require transfusion

 -  No gastrointestinal bleeding

 -  No active systemic infection

 -  No known or suspected hypersensitivity to human albumin

 -  No known or suspected hypersensitivity to mammalian cell-derived products

 -  No uncontrolled diabetes

 PRIOR CONCURRENT THERAPY:

 Biologic therapy

 -  More than 30 days since prior epoetin alfa

 Chemotherapy

 -  More than 21 days since prior chemotherapy

 -  No more than 2 different types of prior chemotherapy regimens for hormone-refractory
 prostate cancer

 Endocrine therapy

 -  See Disease Characteristics

 -  More than 30 days since prior corticosteroids for hormone-refractory prostate cancer

 -  Episodic use of low-dose steroids for other causes is allowed

 Radiotherapy

 -  More than 21 days since prior radiotherapy

 -  Concurrent radiotherapy allowed

 Surgery

 -  See Disease Characteristics

 Other

 -  More than 8 weeks since prior blood transfusion

 -  No concurrent oral or intravenous antibiotics